GILEAD SCIENCES, INC. is 8.3x more valuable than Moderna, Inc. by market capitalization ($151.05 B vs $18.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MRNA | GILD |
|---|---|---|
| Market cap | $18.25 B | $151.05 B |
| US-listed rank | #650 | #99 |
| Revenue (latest FY) | $1.94B | $29.44B |
| Net income (latest FY) | -$2.82B | $8.51B |
| Net margin | -145.2% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 1,447 | 981 |
GILEAD SCIENCES, INC. is 8.3x more valuable than Moderna, Inc. by market capitalization ($151.05 B vs $18.25 B).
In their latest fiscal years, Moderna, Inc. reported $1.94B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Moderna, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.